Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SMMT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ligufalimab (AK117) | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 3 · NCT07264075 | Recruiting |
| Ivonescimab RP3D | Metastatic Urothelial Carcinoma | Phase 2/3 · NCT07815665 | Recruiting |
| Ivonescimab (AK112) | Non-Small Cell Lung Cancer | Phase 3 · NCT06767514 | Recruiting |
| Ivonescimab Dose 2 | Metastatic Urothelial Carcinoma | Phase 2/3 · NCT07815665 | Recruiting |
| Ivonescimab Dose 1 | Metastatic Urothelial Carcinoma | Phase 2/3 · NCT07815665 | Recruiting |
| Ridinilazole | Clostridioides Difficile Infection | Phase 3 · NCT03595553 | Completed |
| Vancomycin | Clostridioides Difficile Infection | Phase 3 · NCT03595553 | Completed |
| Nebivolol Ophthalmic Suspension 0.5 Percent | Open-Angle Glaucoma | Phase 2 · NCT04910100 | Completed |
| Nebivolol Ophthalmic Suspension 1 Percent | Open-Angle Glaucoma | Phase 2 · NCT04910100 | Completed |
| Cadonilimab | Renal Cell Carcinoma, Clear Cell | Phase 2 · NCT07877194 | Not yet recruiting |
| Osimertinib | Non-Small Cell Lung Cancer | Phase 1/2 · NCT07535437 | Recruiting |
| Nab-paclitaxel | Non Small Cell Lung Cancer | Phase 2 · NCT07234877 | Not yet recruiting |
| Timolol Ophthalmic Solution 0.5 Percent | Open-Angle Glaucoma | Phase 2 · NCT04910100 | Completed |
| Timolol Ophthalmic Suspension 0.5 Percent | Open-Angle Glaucoma | Phase 2 · NCT04910100 | Completed |
| Zoldonrasib | Advanced Solid Tumors | Phase 1/2 · NCT07397338 | Recruiting |
| Datopotamab Deruxtecan | Non-Small Cell Lung Cancer | Phase 1/2 · NCT07535437 | Recruiting |
Also used in these trials (approved or third-party drugs, not SMMT's own candidates): Pembrolizumab, Oxaliplatin, Enfortumab Vedotin, Ipilimumab, Leucovorin, Paclitaxel, Pemetrexed Disodium, Daraxonrasib, Bevacizumab, Capecitabine, Carboplatin, Cetuximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SMMT had $629.8M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $2.6B pro forma, before operating spending after that date:
It burns about $150.5M/quarter from operations, an estimated runway of 52.4 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SMMT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Robert W Duggan Co-Chief Executive Officer, Director, 10 · +16.19M options |
Insider | 610,515,809 | 76.34% | 2026-11-16 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10 · +10.81M options Includes shares also reported by Robert W Duggan, counted once |
Insider | 610,515,809 | 76.34% | 2026-11-16 |
| Baker Bros. Advisors, LP | Institution (13F) | 32,786,348 | 4.10% | 2026-09-30 |
| Yu Xia Director · +40,438 options |
Insider | 32,057,147 | 4.01% | 2025-10-21 |
| Blackrock Inc. | Institution (13F) | 10,363,750 | 1.30% | 2026-09-30 |
| FMR, LLC | Institution (13F) | 8,136,745 | 1.02% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 7,230,441 | 0.90% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 6,717,642 | 0.84% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 6,093,474 | 0.76% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 5,296,215 | 0.66% | 2026-09-30 |
| Citadel Advisors Llc | Institution (13F) | 3,783,589 | 0.47% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 3,489,224 | 0.44% | 2026-09-30 |
Share count 799,763,918 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-16 filed 2026-11-16 |
DUGGAN ROBERT W |
Option exercise (M) | 500,000 | $1.06 | 531,000 |
| 2026-11-16 filed 2026-11-16 |
DUGGAN ROBERT W |
Option exercise (M) | 500,000 | – | – |
| 2026-11-16 filed 2026-11-16 |
Zanganeh Mahkam |
Option exercise (M) | 500,000 | $1.06 | 531,000 |
| 2026-11-16 filed 2026-11-16 |
Zanganeh Mahkam |
Option exercise (M) | 500,000 | – | – |
| 2026-11-16 filed 2026-11-16 |
Soni Manmeet Singh |
Option exercise (M) | 100,000 | $1.37 | 3,224,375 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-11-14 | ivonescimab | BLA | -7.9% | — | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SMMT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →